ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Provepep Synthesizes Therapeutic Protein

by Ann M. Thayer
October 12, 2015 | APPEARED IN VOLUME 93, ISSUE 40

[+]Enlarge
Credit: Ramin Herati/Wikimedia Commons
One half of the interleukin-10 homodimer.
09340-buscon-crystalcxd.jpg
Credit: Ramin Herati/Wikimedia Commons
One half of the interleukin-10 homodimer.

Provepep, the peptide business of the French fine chemistry group Provence Technologies, says it has synthesized 10 mg of the bioactive homodimer form of interleukin-10, an anti-inflammatory cytokine. In doing so, it claims to be one of only a few labs able to chemically synthesize large therapeutic proteins. Provepep used solid-phase peptide synthesis to make segments of the protein and its bis(2-sulfanylethyl)amido ligation technology to join them into a 160 amino acid-long IL-10 subunit.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment